QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:XLO

Xilio Therapeutics - XLO Stock Forecast, Price & News

$3.65
-0.32 (-8.06%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.50
$4.07
50-Day Range
$1.97
$4.28
52-Week Range
$1.95
$14.86
Volume
144,612 shs
Average Volume
97,423 shs
Market Capitalization
$100.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Xilio Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
208.2% Upside
$11.25 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Xilio Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.12) to ($2.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

185th out of 1,055 stocks

Pharmaceutical Preparations Industry

86th out of 518 stocks


XLO stock logo

About Xilio Therapeutics (NASDAQ:XLO) Stock

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
XLO Xilio Therapeutics, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Xilio Therapeutics GAAP EPS of -$0.90
Xilio Therapeutics, Inc. (XLO)
See More Headlines
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.25
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+208.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-75,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.95 per share

Miscellaneous

Free Float
26,510,000
Market Cap
$100.27 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Rene Russo BCPS (Age 48)
    Pharm.D, Pharm.D., CEO & Director
    Comp: $873.8k
  • Dr. Martin H. Huber M.D. (Age 62)
    Pres and Head of R&D
    Comp: $739.46k
  • Mr. Edward C. English (Age 56)
    VP of Fin. & Accounting, Treasury and Principal Accounting Officer
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Mr. Christopher Frankenfield
    Chief Legal & Admin. Officer
  • Julissa Viana
    VP of Corp. Communications
  • Mr. Bill Avery Ph.D.
    Sr. VP of Nonclinical Devel.
  • Ms. Stacey J. Davis
    Chief Bus. Officer













XLO Stock - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares.
View XLO analyst ratings
or view top-rated stocks.

What is Xilio Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12 month price objectives for Xilio Therapeutics' shares. Their XLO share price forecasts range from $7.00 to $15.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 183.4% from the stock's current price.
View analysts price targets for XLO
or view top-rated stocks among Wall Street analysts.

How have XLO shares performed in 2023?

Xilio Therapeutics' stock was trading at $2.69 on January 1st, 2023. Since then, XLO shares have increased by 47.6% and is now trading at $3.97.
View the best growth stocks for 2023 here
.

Are investors shorting Xilio Therapeutics?

Xilio Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 19,200 shares, a decline of 31.4% from the December 31st total of 28,000 shares. Based on an average trading volume of 35,800 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are sold short.
View Xilio Therapeutics' Short Interest
.

When is Xilio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our XLO earnings forecast
.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Wednesday, November, 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.17.

When did Xilio Therapeutics IPO?

(XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

What is Xilio Therapeutics' stock symbol?

Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO."

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xilio Therapeutics' stock price today?

One share of XLO stock can currently be purchased for approximately $3.97.

How much money does Xilio Therapeutics make?

Xilio Therapeutics (NASDAQ:XLO) has a market capitalization of $109.06 million. The company earns $-75,800,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis.

How can I contact Xilio Therapeutics?

The official website for the company is www.xiliotx.com. The company can be reached via phone at 857-524-2466 or via email at monique@thrustsc.com.

This page (NASDAQ:XLO) was last updated on 1/31/2023 by MarketBeat.com Staff